Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isothiocyanate SCHEMBL3612486 | 0.89 | MAPK1 (0.35) | MAPK1TDP1CYP3A4TSHRTRPA1 | |
| SCHEMBL7921988 | 0.84 | MAPK1 (0.44) | MAPK1TDP1CYP3A4TSHRTRPA1 | |
| SCHEMBL4240933 | 0.84 | CYP3A4 (0.41) | MAPK1TDP1CYP3A4TSHRTRPA1 | |
| SCHEMBL30858740 | 0.81 | TRPA1 (0.35) | MAPK1TDP1CYP3A4TRPA1 | |
| SCHEMBL21239456 | 0.81 | TRPA1 (0.35) | MAPK1TDP1CYP3A4TRPA1 | |
| SCHEMBL60268 | 0.81 | RXRA (0.34) | MAPK1TDP1CYP3A4TSHRTRPA1 | |
| SCHEMBL131042 | 0.80 | TDP1 (0.50) | MAPK1TDP1CYP3A4TSHRTRPA1 | |
| SCHEMBL27805581 | 0.80 | CYP3A4 (0.38) | MAPK1TDP1CYP3A4TSHRTRPA1 | |
| SCHEMBL29849778 | 0.78 | TDP1 (0.39) | MAPK1TDP1CYP3A4TSHRTRPA1 | |
| SCHEMBL160448 | 0.77 | GABRA1 (0.35) | MAPK1TDP1CES2CES1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431706-A | Fatigue-resistant polyurethane elastomer and preparation method and application thereof | 万勋科技(深圳)有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-118834461-B | Polyethylene composite flame-retardant waterproof material and preparation method thereof | 浙江航华网业有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-105944701-A | Preparation method of bonded nanocellulose chiral stationary phase | 中国科学院兰州化学物理研究所 | 2016-09-21 | — | — | CN | claimed |
| CN-104741102-A | A preparing method of a surface organic-inorganic hybrid core-shell type polysaccharide chiral stationary phase | LANZHOU CHEM PHYS INST | 2015-07-01 | — | — | CN | claimed |
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2025-03-06 | — | — | US | disclosed |
| CN-119431706-A | Fatigue-resistant polyurethane elastomer and preparation method and application thereof | 万勋科技(深圳)有限公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-4460492-A1 | COMPOUNDS CONTAINING A HYDROXYPHENYL MOIETY AND THEIR USE | (INSERM) Institut National de la Santé et de la Recherche Médicale (FR) | 2024-11-13 | — | — | EP | disclosed |
| CN-118834461-A | Polyethylene composite flame-retardant waterproof material and preparation method thereof | 浙江航华网业有限公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4433453-A1 | NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS | Icagen, LLC (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-118525003-A | Novel heteroaryl urea compounds as KV7.2 inhibitors | 伊卡根有限责任公司 | 2024-08-20 | — | — | CN | disclosed |
| WO-2023091554-A9 | NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS | ICAGEN, LLC (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-114072387-B | Indazole compound, pharmaceutical composition and application thereof | 暨南大学 | 2024-03-08 | — | — | CN | disclosed |
| WO-2003062206-A2 | SMALL MOLECULE MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003057220-A1 | CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY | GLAXO GROUP LIMITED (GB) | 2003-07-17 | — | — | WO | disclosed |
| US-5670456-A | Compounds | SANDOZ LTD. (CH) | 1997-09-23 | — | — | US | disclosed |
| US-5506191-A | Heterocyclic hydrazines and hydrazones | SANDOZ LTD. (CH) | 1996-04-09 | — | — | US | disclosed |
| EP-0241559-B1 | OXAZOLIDINEDIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND HERBICIDES CONTAINING THE SAME | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-10-30 | — | — | EP | disclosed |
| US-4983751-A | Chemical intermediates | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-01-08 | — | — | US | disclosed |
| US-4818272-A | NONPHYTOTOXICITY FOR CROPS HELICAL STREAMS | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1989-04-04 | — | — | US | disclosed |
| EP-0241559-A1 | OXAZOLIDINEDIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND HERBICIDES CONTAINING THE SAME | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1987-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A43, F12 | MAPK1 2595/4885TDP1 2961/4885CYP3A4 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.